Five decades of therapy for multiple myeloma: a paradigm for therapeutic models
Open Access
- 31 March 2005
- journal article
- keynote address
- Published by Springer Nature in Leukemia
- Vol. 19 (6) , 910-912
- https://doi.org/10.1038/sj.leu.2403728
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's MacroglobulinemiaLeukemia & Lymphoma, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Multiple Myeloma: How Did It Begin?Mayo Clinic Proceedings, 1994
- THE NATURE OF BENCE-JONES PROTEINSThe Journal of Experimental Medicine, 1962
- CLINICAL EXPERIENCES WITH SARCOLYSIN IN NEOPLASTIC DISEASESAnnals of the New York Academy of Sciences, 1958
- Urethane in Multiple Myeloma IActa Medica Scandinavica, 1952
- URETHANE AND STILBAMIDINE IN MULTIPLE MYELOMA *1REPORT ON TWO CASESThe Lancet, 1947